The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letter to the EditorFull Access

To the Editor:

Drs. Brady and Sinha described a neurobiological and behavioral model of comorbid substance use and psychiatric disorders in which substance use by vulnerable individuals may be both an attempt to medicate preexisting chronic stress and a cause of continuing stress. Extraordinarily high nicotine use in schizophrenia, however, could relate to nicotine’s ability to attenuate sensory gating deficits indicative of disordered nicotinic transmission, as the authors suggested. Indeed, alpha-7 nicotinic receptors (α7-nAChRs) are reduced in the brain by approximately 50% (1) and in peripheral blood by up to 90% (2) in schizophrenia patients, regardless of smoking history. We hypothesize that low α7-nAChRs also impair stress regulation in schizophrenia. A possible mechanism involves anandamide, an endogenous cannabinoid that dampens hypothalamic stress activation (3). However, anandamide formation, at least in rat cortical neurons, requires α7-nAChR activation (4). Evidence that nicotine or exogenous cannabinoids can reverse attentional and stress-related cognitive deficits in rodents and humans (57) suggests that these agents target common pathways.

Anandamide’s stress regulation may also depend on the availability of its precursor, arachidonic acid, which is low in some schizophrenia patients. In a preliminary study, we found that former cannabis users with schizophrenia, but not cannabis-naive patients, show an inverse relationship between stress and arachidonic acid and other fatty acids that support anandamide (8). Currently, we are exploring interactions between fatty acids, endocannabinoids, nicotinic deficits, and stress (FENDS) in schizophrenia.

Drs. Brady and Sinha suggested that nicotinic receptors are potential therapeutic targets. In addition, cannabinoid agonists and antagonists, fatty acid supplementation, dietary modification, and cognitive behavior reframing of responses to stressors could potentially ameliorate the putative FENDS interactions in schizophrenia.

References

1. Leonard S, Breese C, Adams C, Benhammou K, Gault J, Stevens K, Lee M, Adler L, Olincy A, Ross R, Freedman R: Smoking and schizophrenia: abnormal nicotinic receptor expression. Eur J Pharmacol 2000; 393:237–242Crossref, MedlineGoogle Scholar

2. Perl O, Ilani T, Strous RD, Lapidus R, Fuchs S: The alpha7 nicotinic acetylcholine receptor in schizophrenia: decreased mRNA levels in peripheral blood lymphocytes. FASEB J 2003; 17:1948–1950Crossref, MedlineGoogle Scholar

3. Di S, Malcher-Lopes R, Halmos KC, Tasker JG: Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci 2003; 23:4850–4857Crossref, MedlineGoogle Scholar

4. Stella N, Piomelli D: Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol 2001; 425:189–196Crossref, MedlineGoogle Scholar

5. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, Gorzalka BB: Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005; 30:508–515Crossref, MedlineGoogle Scholar

6. Ingram N, Martin S, Wang J, van der Laan S, Loiacono R, van den Buuse M: Interaction of corticosterone and nicotine in regulation of prepulse inhibition in mice. Neuropharmacology 2005; 48:80–92Crossref, MedlineGoogle Scholar

7. Solowij N: Cannabis and Cognitive Functioning. Cambridge, UK, Cambridge University Press, 1998Google Scholar

8. Monterrubio S, Solowij N, Meyer BJ, Turner N: Fatty acid relationships in former cannabis users with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (in press)Google Scholar